Aberrant expression of notch3 predicts poor survival for hepatocellular carcinomas

BioScience Trends

Volumn 7, Issue 3, 2013, Pages 152-156

  Hu, Lei ^a   Xue, Feng ^a   Shao, Minhua ^b   Deng, Anmei ^c   Wei, Gongtian ^a  

^a The Fourth Department of Liver Surgery Eastern Hepatobiliary Hospital Affiliated to the Second Military Medicine College   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinomas; Immunohistochemistry; Notch pathway; Notch3; Prognosis

Indexed keywords

NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; PROGNOSIS; RECEPTORS, NOTCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84880585219     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2013.v7.3.152     Document Type: Article

References (17)

1. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010; 42(Suppl 3):S206-S214.
2. Dang TP. Notch, apoptosis and cancer. Adv Exp Med Biol. 2012; 727:199-209.
3. Ambler CA, Maatta A. Epidermal stem cells: Location, potential and contribution to cancer. J Pathol. 2009; 217:206-216.
4. Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol. 2012; 727:305-319.
5. Gramantieri L, Giovannini C, Lanzi A, Chieco P, Ravaioli M, Venturi A, Grazi GL, Bolondi L. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int. 2007; 27:997-1007.
6. Gao J, Song Z, Chen Y, Xia L, Wang J, Fan R, Du R, Zhang F, Hong L, Song J, Zou X, Xu H, Zheng G, Liu J, Fan D. Deregulated expression of Notch receptors in human hepatocellular carcinoma. Dig Liver Dis . 2008; 40:114-121.
7. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9:166-180.
8. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007; 141:330-339.
9. Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama S, Otsuki Y, Miyazaki K. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. Am J Clin Pathol. 2012; 138:535-544.
10. Zhao C, Chen Y, Zhang W, Zhang J, Xu Y, Li W, Chen S, Deng A. Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance. Onco Targets Ther. 2013; 6:183-188.
11. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: A new approach to the development of cell fate modifying agents. Oncogene. 2003; 22:6598-6608.
12. Serafin V, Persano L, Moserle L, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol. 2011; 224:448-460.
13. Yamaguchi N, Oyama T, Ito E, et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res. 2008; 68:1881-1888.
14. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A, Carbone DP, Dang TP. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res. 2005; 65:3555-3561.
15. Giovannini C, Lacchini M, Gramantieri L, Chieco P, Bolondi L. Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res. 2006; 26:2123-2127.
16. Giovannini C, Gramantieri L, Minguzzi M, Fornari F, Chieco P, Grazi GL, Bolondi L. CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma. Am J Pathol. 2012; 181:413-422.
17. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, Ramazzotti E, Marcu KB, Bolondi L. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol. 2009; 50:969-979.